preladenant preladenant preladenant (sch 420814) was a drug that was developed by schering-plough which acted as a potent and selective antagonist at the adenosine a2a receptor. it was being researched as a potential treatment for parkinson's disease. positive results were reported in phase ii clinical trials in humans, but it did not prove itself to be more effective than a placebo during phase iii trials, and so was discontinued in may 2013. preladenantclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status investigational identifiers iupac name 2-(2-furanyl)-7--1-piperazinyl]ethyl]7h-pyrazolotriazolopyrimidine-5-amine cas number377727-87-2 npubchem cid10117987iuphar/bps5614chemspider8293510 nunii950o97nupokeggd09717comptox dashboard (epa)dtxsid90191219 echa infocard100.210.813 chemical and physical dataformulac25h29n9o3molar mass503.567 g·mol−13d model (jsmol)interactive image smiles coccoc(cc4)ccc4n(cc3)ccn3ccn(c2nc1n)ncc2c(n5)n1nc5-c6occc6 inchi inchi=1s/c25h29n9o3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17h,8-13,15-16h2,1h3,(h2,26,29) nkey:dtywjkssuanmhd-uhfffaoysa-n n ny (what is this?) (verify)